Biochemical study of novel phosphate paracetamol prodrug invivo and invitro

1. Gilchrist, Fiona M., The activity of pH membrane disruptive pseudo peptides and their subcellular fate in mammalian cells cultured in-vitro. Ph.D thesis, Aston University, Birmingham, 2002. 
2. Nicholas B.,  Teruo M.,  Whei-Mei Wu., “Soft Drugs 18. Oral and Rectal Delivery of Loteprednol Etabonate, a Novel Soft Corticosteroid, in Rats—for Safer Treatment of Gastrointestinal Inflammation” Pharmaceutical Research, 1995, Vol. 12, No. 6, p. 869-874. 
3. C. G. Wermuth, C. R., Ganellin, P., Lindberg and L. A. Mitscher., “Glossary of terms used in medicinal chemistry” Pure Appl. Chem., 1998, Vol. 70, No. 5, p. 1129-1143.
4. Kelemen Hajnal1, Hancu Gabriel1*, Rusu Aura1, Varga Erzsébet2, Székely Szentmiklósi Blanka1Acta Medica Marisiensis “Prodrug Strategy in Drug Development” 2016;62(3):356-362
5. Heimbach T., Fleisher D., Kaddoumi A., Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery In Prodrug, The American Association of Pharmaceutical Scientists, New York, Vol. V, 2007.
6. Heimbach, T., Oh  D.M., Li. Y., Rodriguez-Hornedo  N., Garcia, G., Fleisher D., “Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs” Int J Pharm, 2003, Vol. 261, No. 1, p. 81-92.
7. Roopa, R., Maruthi Prasad, B. V. and Vishwanath, H. L.”Serum cholinestarasein relationto indices as cardiocardio-viscular riskassessment marker in type 2 dibetes mellitus” International Journal of Current Research, Vol. 7, Issue, 12, pp.23904-23907, December, 2015
8.  Miroslav Pohanka “Electrochemical Biosensors based on Actylcholinesterase and Butyrylcholinestarase. A Review “Int. J. Electrochem. Sci., Vol. 11, 2016
9. Rui Wang Xi Can Tang " Neuroprotective Effects of Huperzine A A Natural Cholinesterase Inhibitor for the Treatment of Alzheimer’s Disease  " Neurosignals 2005;14:71–82
10. 10.   Barash PG, Cullen BF, Stoelting RK (2006). Handbook of Clinical Anesthesia (5th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 546–9..
11. 11.  M. Pohanka, Int. J. Mol. Sci., 15 (2014) 980912. Stella, V. J., Charman, W. N. & Naringrekar, V. H.Prodrugs. Do they have advantages in clinical practice? Drugs 29, 455–473 (1985).

12. H .Bashar، A. Hameed  F. Maher “ Synthises of two new phosphate paracetamol prodrugs and study their effect on alkalaine phphspatase which purified from serum of diabetic patients” A MSc. thesis،college of science،Tikrit university، 2013

13. AL-Rawi,I.A.,Hebeeb, R.M., and Rabbafat,H.R., Bulletin of Health Research Vol.28 pp.73,1987

1. 14.  Vandekar،M.J.,WHO/VBS VOL.78,692,1978

15. Mahendrakar S. and Dipes R. DASGUP” Purification of the enzyme acetylcholinesterase (AChE. 3.1.1.7)from Meloidogyne incognita and Heterodera  zeaeRevue Nématol.” 14 (4) : 51 7-52{ (1991)

16. Wilson and Gisvold "Drug Latentiation and prodrugs " 1998,P123-137

17. Emilia Krajewska,IIya Zavodnik,Beata Kluska،et.al “Acetylcholinesterase activity of normal and diabetic human erythrocyte membranes: the effect of oxidative agent” Biochemistry and molecular biology international p 203-210,VOl42,No 1, June 1997.

18. Inacio L.G., Stefanello F, Sausen L.D., Maria M.V., Schetinger M.R. &Goncalves J.F (,2006). “ Serum cholinesterase activity in diabetes and associated pathologies ” Diabetes Res .72(1):28-32.

19. Rose, L.,Davis, D.A.andLehmaan, H.,Lancet(1965). pp 225,563

20. Rubins, H.B., Robins, S.J., Collins, D. (2002).Treating Diabetic Dyslipidemia with Gemfibrozil for secondary prevention of coronary Heart Diseaes. Veterans Affairs High-Density Cholesterol Intervention trial study Group. N EnglJ.Med.341:410-8.

21. Magarian EO, Dietz AJ (1 987). Correlation of cholinesterase with serum lipids and lipoproteins.J ClinPharmacol. 21:819-820

22. Cucuianu M, Opincaru A, Tapalaga D (1978).Similar behaviour of lecithin-cholesterol acyltransferase and pseudocholinesterasein liver disease and hyperlipoproteinemia .ClinChimActa85 :73–79.

1. 23.  Nelson, D.L. Cox,M.M.(2008)."Lehninger Principles of  Biochemistry" . 5th Ed. 1 NewYork, USA :PP:209,210

24. White, A. Handler, P. & Smith, E. (1973). "Principles of  biochemistry". 2nd ed. Mc Grow-Hill book company Ablakiston puplication, New York.

25. Ahmed M, Latif N, Khan RA Ahmad A, Rocha JBT, Mazzanti CM, Bagatini MD،Morsch, Schetinger MRC،“Enzymatic and biochemical characterization of Bungarus sindanus snake venom acetylcholinesterase”,J Venom Anim Toxins incl Trop Dis، 2012,  volume 18  issue 2

26. ASSIRI.A.M “Cholinestarase in plasma :Purification and some Biochemical Properties” Jour.Chem.Soc.Pak.Vol.25,No.1,2003

27. K. A. LORD “The Partial Purification and Properties of a Cholinesterase from Blatella  germanica L.” Bsochem. J. (1961) 78, 483

28. Vivek Kumar Gupta, Abhishek Kumar, Nikhat Jamal Siddiqi and Bechan Sharma” Rat Brain Acetyl Cholinesterase as a Biomarker of Cadmium Induced Neurotoxicity” Journal of Toxicology  Volume 1 Issue 1 - January, 2016

29. Catherine Megan Crowch and Edward Jonathan Okello “Kinetics of acetylcholinesterase inhibitory activities byaqueous extracts of Acacia nilotica (L.) and Rhamnus prinoides (L’Hér.)”,African Journal of Pharmacy and Pharmacology Vol. 3(10). pp. 469-475, October, 2009

30. Wasim Ahmed, Mushtaq Ahmad, Rahmat A Khan and Nadia Mustaq

31. Promising inhibition of krait snake’s venom acetylcholinesterase by Salix nigra and its role as anticancer, antioxidant agent Indian J. Anim. Res., 50 (3) 2016:317-323

32. Ji Young Kim, Woo Song Lee, Young Soo Kim, Marcus J. Curtis-Long, Byong Won Lee, YoungBae Ryu, and Ki Hun Park “Isolation of Cholinesterase-Inhibiting Flavonoids from Morus lhou” J. Agric. Food Chem. 2011, 59, 4589–4596

33. Balqiz,W,K.,”The effect new pyrazol derivatives and shiff bases on the activity of acetyl choline esterase in human serum”MSc.thesis Al-Mustansirya Unversity، college of Science,2001

34. Marcella Gabrielle Mendes Machado, Paulo Renato Yamasaki, Jean Leandro dos Santos and Chung Man Chin “Targeted Prodrug Design for the Treatment of Malignant Melanoma”Journal of Dermatology Research and Therapy Volume 2,Issue 2،2016

35. Jun-ichi Yokoe, Norio Iwasaki, Shunji Haruta, Keitaro Kadono, Ken-ichi Ogawara,

36. Kazutaka Higaki, Toshikiro Kimura. “A nalysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model”. Journal of Controlled Release 86 (2003) 305–313.

37. Joachim Brouwers, Jan Tack, Patrick Augustijns .” In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system:Illustration of intraluminal supersaturation” . International Journal of Pharmaceutics 336 (2007) 302–309

38. Hanna Kumpulainen, Tomi Ja¨ rvinen, Anne Mannila, Jukka Leppa¨nen,Tapio Nevalainen, Antti Ma¨ntyla, Jouko Vepsa¨ la¨ inen, Jarkko Rautio.” Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol”. european journal of pharmaceutical sciences 34 ( 2 0 0 8 ) 110–117.

39. Qiong Xie, Xiaolin Wang, Xinghai Wang, Zhiqiang Jiang and Zhuibai Qiu.” Design, synthesis, and bioavailability evaluation of coumarin-based prodrug of meptazinol”. Bioorganic & Medicinal Chemistry Letters 15 (2005) 4953–4956

40. - Arik Dahan, Revital Duvdevani, Eran Dvir, Anat Elmann, Amnon Hoffman.” A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine In-vivo and in-vitro evaluation of an indomethacin–lecithin conjugate”. Journal of Controlled Release 119 (2007) 86–93.

41. Fábio Pedrosa Lins Silva, Bruna Braga Dantas, Gláucia Veríssimo Faheina Martins,Demétrius Antônio Machado de Araújo  and Mário Luiz Araújo de Almeida Vasconcellos .“Synthesis and Anticancer Activities of Novel Guanylhydrazone and Aminoguanidine Tetrahydropyran Derivatives” Molecules 2016, 21, 671

42. Wisut Wichitnithad, Ubonthip Nimmannit،Sumrit Wacharasindhu Pornchai and Rojsitthisak “Synthesis, Characterization and Biological Evaluation of Succinate Prodrugs of Curcuminoids for Colon Cancer Treatment” Molecules 2011, 16

43. Kis B, Snipes JA, Busija DW. "Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties". J. Pharmacol. Exp. Ther. 315(1): (2005)

44. Aronoff DM, Oates JA, Boutaud O. "New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases". Clin. Pharmacol. Ther. (2006) 79 (1): 9–19..

45. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. "Paracetamol: new vistas of an old drug". CNS drug reviews 12 (3–4): (2006) 250–75.

1. 46.  Graham GG, Scott KF. "Mechanism of action of paracetamol". American journal of therapeutics 12 (1): (2005) 46–55.
2. 47.  Chandrasekharan NV, Dai H, Roos KL, et al . "COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression". Proc. Natl. Acad. Sci. U.S.A. 99 (21): (2002) 13926–31.

48. Sallie R, Tredger J (1991). Drugs and the liver. Biopharm. Dru. Dispos. 12: 251-259.

49. Nuduka N (1999). Clinical biochemistry for students of pathology, Longman Nigerian Plc. pp. 1–236

50. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ (2002). Mechanisms of hepatotoxicity. Toxicol. Sci. 65:166–176.

51. Gardner CR, Heck DE, Yang CS, Thomas PE, Zhang XJ, de George GL (1998). Role of nitric oxide in acetaminophen-induced hepatotoxicity in the rat. Hepatol. 26:748–754.

52. Gardner CR, Laskin JD, Dambach DM, Sacco M, Durham SK, Bruno MK, Cohen SD, Gordon MK, Gerecke DR, Zhou P, Laskin DL (2002). Reduced hepatotoxicity of acetaminophen in mice lacking inducible nitric oxide synthase: potential role of tumor necrosis factor-alpha, interleukin-10. Toxicol. Appl. Pharmacol. 184:27–36.

53. Kuvandik G, Duru M, Nacar A, Yonden Z, Helvaci R, Koc A, Kozlu T, Kaya H, Sogüt S (2008). Effects of erdosteine on acetaminophen-induced hepatotoxicity in rats. Toxicol. Pathol. 36:714-719.

54. Kanchana N, Sadiq AM (2011). hepatoprotective effect of plumbago zeylanica on paracetamol induced liver toxicity in rats. Int. J. Pharm. Sci. 3(1):151-154

55. Lotková H, Kučera O, Roušar T, Endlicher R, Křiváková P, Garnol T, Červinková Z (2009). Effect of S-adenosyl methionine on acetaminophen acetaminophen-induced toxic injury of rat hepatocytes in vitro ACTA. VET. BRNO. 78:603-613.

56. Abdel-Azeem AS, Hegazy AM, Ibrahim KS, Farrag AR, El-Sayed EM (2013). Hepatoprotective, antioxidant and ameliorative effects of ginger (Zingiber officinale Roscoe) and vitamin E in acetaminophen treated rats. J. Diet. Suppl. 10(3):195-209.

57. Mohamed A Lebda*, Nabil M Taha, Mahdy A Korshom, Abd El-Wahab A Mandour and Raghda I Goda” Ginger (Zingiber officinale) potentiate paracetamol induced chronic hepatotoxicity in Rats” Journal of Medicinal Plants Research Vol. 7(42), pp. 3164-3170, 10 November, 2013.

58. Setty SR, Quereshi AA, Swamy AHMV, Patil T, Prakash T, Prabhu K, Gouda AV (2007). Hepatoprotective activity of Calotropis procera flowers against Paracetamol induced hepatic injury in rats. Fitoter. 78(7-8):451–454.

59. Raghavendran HRB, Sathivel A, Devaki T (2005). Effect of Sargassum polycystum (Phaeophyceae)-sulphated polysaccharide extract against acetaminophen-induced hyperlipidemia during toxic hepatitis in experimental rats. Mol. Cell. Biochem. 27(1-2):89–96.